1. Scrip
  2. >>Conferences
  3. >>ASCO

Anti-TROP2 ADCs Lung Cancer Futures Likely Lie In Earlier-Stage Disease

Could Merck/Kelun Come Out On Top?

 
• By Alaric DeArment

The discussant at ASCO’s NSCLC session said the field would need to “manage expectations” as the drugs do not appear to beat chemotherapy in all-comers. 

• Source: Shutterstock

Emerging data on the field of TROP2-targeted antibody-drug conjugates – namely Gilead Sciences, Inc.’s Trodelvy (sacituzumab govitecan-hziy), Daiichi Sankyo Co., Ltd./AstraZeneca PLC’s (datopotamab deruxtecan (Dato-DXd) and Merck & Co., Inc./Sichuan Kelun Pharmaceutical Co Ltd.’s sacituzumab tirumotecan (Sac-TMT) – suggest that developers need to aim for subgroups of non-small cell lung cancer rather than all-comers, and that the drugs are more likely to work in earlier-line disease combined with checkpoint inhibitors.

Key Takeaways

  • ASCO featured Phase II and Phase III data from three competing TROP2-directed ADCs in non-small cell lung cancer, giving a glimpse of the future competitive field.

    ...

Detailed data from Gilead’s failed Phase III EVOKE-01 trial of Trodelvy, the investigator-sponsored Phase II ICARUS-Lung01 trial of Dato-DXd and Kelun’s Phase II OptiTROP-Lung01 trial of Sac-TMT combined with its...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from ASCO

ASCO: Trodelvy First-Line TNBC Data Seen As Potentially Practice-Changing

 
• By Alaric DeArment

Gilead chief medical officer Dietmar Berger said in an interview that the company plans to quickly take the results to regulators and foresees broad first-line use of the drug.

ASCO: Merck’s Zilo-V Shows Activity, But Numbers Still Small

 
• By Alaric DeArment

The drug boosted overall responses on top of the R-GemOx backbone, but the discussant pointed out that patients in waveLINE-003 were not very heavily pretreated.

Ascentage Broadens Horizons As Pipeline Shows Renewed Promise

 
• By Xu Hu

Ascentage will share at ASCO new clinical data on its Bcl-2 inhibitor lisaftoclax, part of the Chinese firm's novel pipeline, on which its CEO shared with Scrip plans and strategy, along with some views on the use of RWD in China.

ASCO Preview: Major Solid Tumor Readouts Include AstraZeneca/Daiichi, Gilead ADCs

 
• By Alaric DeArment

Data from several closely watched solid tumor drug trials – some considered practice-changing – are scheduled for presentation at the meeting, including for AstraZeneca and Daiichi’s Enhertu.

More from Conferences

ASCO Preview: Major Solid Tumor Readouts Include AstraZeneca/Daiichi, Gilead ADCs

 
• By Alaric DeArment

Data from several closely watched solid tumor drug trials – some considered practice-changing – are scheduled for presentation at the meeting, including for AstraZeneca and Daiichi’s Enhertu.

ASCO Preview: Data From Regeneron, J&J/Legend And Others In Hematology

 
• By Alaric DeArment

With the American Society of Clinical Oncology meeting kicking off on 30 May, Scrip will follow the latest in blood cancers, including Regeneron’s linvoseltamab in multiple myeloma and Merck’s ADC zilovertamab vedotin in DLBCL.

Merus Bispecific Impresses In Head And Neck Cancer

 
• By Andrew McConaghie

Updated Phase II results from petosemtamab have impressed ahead of ASCO, outshining Keytruda monotherapy and its bispecific rival from Bicara.